BioAge Labs

Yahoo Finance • 2 days ago

Leqembi® approved for the treatment of early Alzheimer's disease in Australia

STOCKHOLM, Sept. 24, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved lecanemab (Leqembi) for the treatment of adult patients wi... Full story

Yahoo Finance • 15 days ago

FDA Approves BioArctic (OM:BIOA B) Lecanemab Injection For Alzheimer's

BioArctic has seen a significant price movement of 41% over the past quarter. This surge is closely tied to several positive developments, including an impressive earnings report where the company posted a net income of SEK 96 million, rev... Full story

Yahoo Finance • last month

BioArctic signs $30 million deal with Novartis for brain drug delivery tech

STOCKHOLM - BioArctic AB (Nasdaq Stockholm:BIOA B), a pharmaceutical company with a market capitalization of $44.9 billion and an "GREAT" financial health rating according to InvestingPro, has entered into an option, collaboration and lice... Full story

Yahoo Finance • last month

BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties

STOCKHOLM, Aug. 26, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has entered into an option, collaboration and license agreement with Novartis Pharma AG regarding a potential new trea... Full story

Yahoo Finance • last month

BioAge Labs to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the bi... Full story

Yahoo Finance • last month

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial development planned in obesity; BGE-102 demonstrated... Full story

Yahoo Finance • last month

Peptide Synthesis Company Evaluation Report 2025 | Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies Lead with Advanced Instruments, Reagents, and Strategic Expansions

Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Peptide Synthesis Company Evaluation Report" report has been added to ResearchAndMarkets.com's offering. The Peptide Synthesis Market Companies Quadrant is a comprehensive industry analy... Full story

Yahoo Finance • 3 months ago

BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioAge Labs, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against BioAge Labs, Inc. (NASDAQ: BIOA) on behalf of long-term stockholders... Full story

Yahoo Finance • 3 months ago

BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions

Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapy Data support development of next-generation APJ agonists for... Full story

Yahoo Finance • 5 months ago

Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Monolithic Power Systems, Inc. (NASDAQ: MPWR): Grabar Law Office Investigates Claims on Your Behalf

PHILADELPHIA, April 22, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) If you have held BioAge Labs, Inc. (NASDAQ: BIOA) shares continuously since on or shortly after its September 26, 2024 IPO, you can seek corporate reform... Full story

Yahoo Finance • 5 months ago

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)

PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) If you have held BioAge Labs, Inc. (NASDAQ: BIOA) shares continuously since on or shortly after its September 26, 2024 IPO, you can seek corporate reform... Full story

Yahoo Finance • 7 months ago

BIOA DEADLINE TODAY: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge’s registration statement for the in... Full story

Yahoo Finance • 7 months ago

Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story

Yahoo Finance • 7 months ago

DEADLINE ALERT for REGN and BIOA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, March 10, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the... Full story

Yahoo Finance • 7 months ago

BIOA FINAL DEADLINE: BioAge Labs Investors are Encouraged to Contact BFA Law before the Expiration of Today’s Class Action Deadline

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential viola... Full story

Yahoo Finance • 7 months ago

BIOA LEGAL NEWS: A Class Action was filed on behalf of BioAge Labs Investors - Contact BFA Law if You Suffered Losses

NEW YORK, March 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential viola... Full story

Yahoo Finance • 7 months ago

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman

SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) is abandoning development of its lead obesity candidate, azelaprag, just weeks after halting a Phase 2 trial. The biotech firm is pivoting to a preclinica... Full story

Yahoo Finance • 7 months ago

BIOA Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. (BIOA) Investors of Filing Deadline in Class Action Lawsuit

RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Norther... Full story

Yahoo Finance • 7 months ago

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc. (BIOA) Shareholders

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in BioAge Labs, Inc. ("BioAge" or the "Company") (NASDAQ: BIOA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover l... Full story

Yahoo Finance • 7 months ago

BIOA DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – BIOA

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ: BIOA) pursuant and/or traceable to BioAge’s registration statement for the in... Full story